A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (NCT07213674)

🧪 Interventions in This Study

• Xaluritamig (DRUG)
• Abiraterone acetate (DRUG)
• Docetaxel (DRUG)
• Cabazitaxel (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (151 Sites)

Showing the first 25 of 151 sites.

• City of Hope Cancer Center Phoenix — Goodyear, Arizona
• University of Arizona Cancer Center — Tucson, Arizona
• City of Hope National Medical Center — Duarte, California
• City of Hope Orange County Lennar Foundation Cancer Center — Duarte, California
• Providence Saint Jude Medical Center — Fullerton, California
• University of California Irvine — Orange, California
• University of California San Francisco — San Francisco, California
• Providence Saint Johns Health Center — Santa Monica, California
• Rocky Mountain Cancer Centers — Denver, Colorado
• Hartford HealthCare Cancer Institute at Hartford Hospital — Hartford, Connecticut
• Medical Oncology Hematology Consultants Helen F Graham Cancer Center — Newark, Delaware
• Moffitt Cancer Center — Tampa, Florida
• City of Hope Atlanta — Newnan, Georgia
• University of Illinois Chicago — Chicago, Illinois
• Midwestern Regional Medical Center dba City of Hope Chicago — Zion, Illinois
• University of Kansas Medical Center — Westwood, Kansas
• University of Louisville Health - James Graham Brown Cancer Center — Louisville, Kentucky
• Norton Cancer Institute — Louisville, Kentucky
• University of Maryland Greenebaum Cancer Center — Baltimore, Maryland
• Johns Hopkins Hospital Sidney Kimmell Comprehensive Cancer Center — Baltimore, Maryland
• Barbara Ann Karmanos Cancer Institute — Lansing, Michigan
• Minnesota Oncology Hematology PA — Minneapolis, Minnesota
• University of Minnesota Medical Center Fairview — Minneapolis, Minnesota
• Hematology Oncology Association of Central New York — East Syracuse, New York
• Memorial Sloan Kettering Cancer Center — New York, New York

📞 Contact the Study Coordinator

Phone: (866) 572-6436

Email: medinfo@amgen.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Metastatic Castration-resistant Prostate Cancer

• A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer — San Francisco, California
• Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment — Tucson, Arizona
• ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC — Sacramento, California
• FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Duarte, California
• A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer — Duarte, California
• FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer — San Francisco, California

Explore by condition: All Metastatic Castration-resistant Prostate Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.